Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982720priorityCriticalpatent/ECSP982720A/en
Publication of ECSP982720ApublicationCriticalpatent/ECSP982720A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Formulación que contiene un opioide en combinación con un agonista alfa-adenérgico o sales farmacéuticamente aplicables de las sustancias activas y otros excipientes, en que para el agonista alfa-adrenérgicos se utiliza la unidad de dosificación entre 1ug y 500ug, y para el opioide la unidad de dosificación entre 0.5 y 50 mg. evitando la formulación de efectos circulatorios de origen central, y la utilización como analgésico.Formulation containing an opioid in combination with an alpha-adrenergic agonist or pharmaceutically applicable salts of the active substances and other excipients, in which the dosage unit between 1ug and 500ug is used for the alpha-adrenergic agonist, and for the opioid unit dosage between 0.5 and 50 mg. avoiding the formulation of circulatory effects of central origin, and the use as an analgesic.
ECSP9827201998-10-301998-10-30
FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC
ECSP982720A
(en)
PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND FIBRATE AND ITS USE IN THE PREPARATION OF DRUGS INTENDED TO REDUCE HYPERGLYCEMIA.
Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
Method for human in vitro fertilization, use of a hypothalamic hormone and / or pituitary hormone or an agonist or antagonist of the same or an active derivative thereof, pharmaceutical kit in single dosage form, and any new aspect or combination of aspects
Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.